Dyne Therapeutics, Inc.
15.62USD
-0.1500 (-0.95%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on DYN.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | — | — | — | — | 0.0 | 52.8M |
| Q1 | — | — | — | — | — | — |
| Q2 | — | — | — | — | — | — |
| Q3 | — | — | — | — | 0.0 | — |
| Q4 | — | — | — | — | 0.0 | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -3.23 | -3.95 | -3.37 | -3.47 | -3.55 | -3.34 |
| Q1 | -.690 | -.780 | -.810 | -1.05 | -.730 | — |
| Q2 | -1.01 | -1.08 | -.700 | -.970 | -1.08 | — |
| Q3 | -.800 | -.990 | -.960 | -.760 | -.888 | — |
| Q4 | -.730* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| -1.09* |
| -.880* |
| -.730* |
| -.891 |
| — |
Debt level and coverage